UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Inclusion of elderly patients in oncology clinical trials

Annals of oncology, 2016-09, Vol.27 (9), p.1799-1804

2016

Volltextzugriff (PDF)

Changes in the use of end points in clinical trials for elderly cancer patients over time

Annals of oncology, 2017-10, Vol.28 (10), p.2606-2611

2017

Volltextzugriff (PDF)

A single centre study of the treatment of relapsed primary central nervous system lymphoma (PCNSL) with single agent temozolomide

Journal of clinical neuroscience, 2012-11, Vol.19 (11), p.1501-1505

2012

Volltextzugriff (PDF)

A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors

Annals of oncology, 2016-12, Vol.27 (12), p.2268-2274

2016

Volltextzugriff (PDF)

Poor patient-reported outcomes reporting according to CONSORT guidelines in randomized clinical trials evaluating systemic cancer therapy

Annals of oncology, 2015-01, Vol.26 (1), p.231-237

2015

Volltextzugriff (PDF)

153P Safety/tolerability and antitumor activity of sitravatinib plus tislelizumab (TIS) in patients with advanced platinum-resistant ovarian cancer (PROC)

Annals of oncology, 2021-12, Vol.32, p.S1446-S1447

2021

Volltextzugriff (PDF)

747P Phase I study of SAR444245 (SAR’245) as monotherapy (mono) and combined with pembrolizumab (pembro) or cetuximab (cetux) in patients (pts) with advanced solid tumors

Annals of oncology, 2022-09, Vol.33, p.S885-S886

2022

Volltextzugriff (PDF)

1021O Safety and antitumor activity of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with mesothelioma which is relapsed or refractory to standard therapies

Annals of oncology, 2020-09, Vol.31, p.S705-S706

2020

Volltextzugriff (PDF)

The reporting of adverse events in oncology phase III trials: a comparison of the current status versus the expectations of the EORTC members

Annals of oncology, 2016-01, Vol.27 (1), p.192-198

2016

Volltextzugriff (PDF)

Radiologically evident treatment effects in patients with glioblastoma (GBM) and its clinical implications

Annals of oncology, 2018-10, Vol.29, p.viii129-viii130

2018

Volltextzugriff (PDF)

1406PADHERENCE TO CONSORT PATIENT-REPORTED OUTCOMES REPORTING GUIDELINES IN RANDOMIZED CLINICAL TRIALS EVALUATING SYSTEMIC CANCER THERAPY: A SYSTEMATIC REVIEW

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv491-iv491

2014

Volltextzugriff (PDF)

Adherence to Consort Patient-Reported Outcomes Reporting Guidelines in Randomized Clinical Trials Evaluating Systemic Cancer Therapy: a Systematic Review

Annals of oncology, 2014-09, Vol.25, p.iv491

2014

Volltextzugriff (PDF)

Safety and Antitumor Activity of Sitravatinib in Combination with Tislelizumab in Patients With Advanced Solid Tumors: Ovarian Cancer Cohort Data

Annals of oncology, 2019-12, Vol.30, p.xi34-xi35

2019

Volltextzugriff (PDF)

Aggregated adverse-events outcomes in oncology phase III reports: A systematic review

European journal of cancer (1990), 2016-01, Vol.52, p.26-32

2016

Volltextzugriff (PDF)

Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, with temozolomide (TMZ) in recurrent glioblastoma (rGBM)

Annals of oncology, 2016-10, Vol.27, p.vi103-vi103

2016

Volltextzugriff (PDF)

28PD Identifying the correct patient (pt) population for ABT-414: Biomarker assays for epidermal growth factor receptor (EGFR) in pts with glioblastoma (GBM)

Annals of oncology, 2015-12, Vol.26, p.ix8-ix8

2015

Volltextzugriff (PDF)

138O Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, with temozolomide (TMZ) in recurrent glioblastoma (rGBM)

Annals of oncology, 2016-12, Vol.27 (suppl_9)

2016

Volltextzugriff (PDF)

138O Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, with temozolomide (TMZ) in recurrent glioblastoma (rGBM)

Annals of oncology, 2016-12, Vol.27, p.ix42-ix42

2016

Volltextzugriff (PDF)

A Phase 1 Study Evaluating Abt-414 with Concurrent Radiotherapy (Rt) and Temozolomide (Tmz) in Newly Diagnosed Glioblastoma (Gbm)

Annals of oncology, 2014-09, Vol.25, p.iv138

2014

Volltextzugriff (PDF)

416OA PHASE 1 STUDY EVALUATING ABT-414 WITH CONCURRENT RADIOTHERAPY (RT) AND TEMOZOLOMIDE (TMZ) IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM)

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv138-iv138

2014

Volltextzugriff (PDF)

Managing toxicities and optimal dosing of targeted drugs in advanced kidney cancer

Current oncology (Toronto), 2009-05, Vol.16 Suppl 1 (11), p.S52-59

2009

Volltextzugriff (PDF)

Targeted therapies for renal cell carcinoma: more gains from using them again

Current oncology (Toronto), 2009-05, Vol.16 Suppl 1 (Suppl 1), p.S45-S51

2009

Volltextzugriff (PDF)

The Significance of Tracheobronchial Collapse in Obstructive Emphysema

Respiration, 1965, Vol.22 (2), p.244-257

1965

Volltextzugriff (PDF)

Remediation of soils contaminated with polycyclic aromatic hydrocarbons (PAHs)

Journal of hazardous materials, 2009-12, Vol.172 (2), p.532-549

2009

Volltextzugriff (PDF)

Simulation-based evolutionary optimization for energy-efficient layout plan design of high-rise residential buildings

Journal of cleaner production, 2019-09, Vol.231, p.1375-1388

2019

Volltextzugriff (PDF)

1 – 25 von 46

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(41)
Mit Volltextzugriff
(45)

Publikationsform

Artikel
(41)
Tagungsberichte
(5)

Sprache

Englisch
(46)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Inclusion of elderly patients in oncology clinical trials

Changes in the use of end points in clinical trials for elderly cancer patients over time

A single centre study of the treatment of relapsed primary central nervous system lymphoma (PCNSL) with single agent temozolomide

A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors

Poor patient-reported outcomes reporting according to CONSORT guidelines in randomized clinical trials evaluating systemic cancer therapy

153P Safety/tolerability and antitumor activity of sitravatinib plus tislelizumab (TIS) in patients with advanced platinum-resistant ovarian cancer (PROC)

747P Phase I study of SAR444245 (SAR’245) as monotherapy (mono) and combined with pembrolizumab (pembro) or cetuximab (cetux) in patients (pts) with advanced solid tumors

1021O Safety and antitumor activity of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with mesothelioma which is relapsed or refractory to standard therapies

The reporting of adverse events in oncology phase III trials: a comparison of the current status versus the expectations of the EORTC members

Radiologically evident treatment effects in patients with glioblastoma (GBM) and its clinical implications

1406PADHERENCE TO CONSORT PATIENT-REPORTED OUTCOMES REPORTING GUIDELINES IN RANDOMIZED CLINICAL TRIALS EVALUATING SYSTEMIC CANCER THERAPY: A SYSTEMATIC REVIEW

Adherence to Consort Patient-Reported Outcomes Reporting Guidelines in Randomized Clinical Trials Evaluating Systemic Cancer Therapy: a Systematic Review

Safety and Antitumor Activity of Sitravatinib in Combination with Tislelizumab in Patients With Advanced Solid Tumors: Ovarian Cancer Cohort Data

Aggregated adverse-events outcomes in oncology phase III reports: A systematic review

Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, with temozolomide (TMZ) in recurrent glioblastoma (rGBM)

28PD Identifying the correct patient (pt) population for ABT-414: Biomarker assays for epidermal growth factor receptor (EGFR) in pts with glioblastoma (GBM)

138O Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, with temozolomide (TMZ) in recurrent glioblastoma (rGBM)

138O Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, with temozolomide (TMZ) in recurrent glioblastoma (rGBM)

A Phase 1 Study Evaluating Abt-414 with Concurrent Radiotherapy (Rt) and Temozolomide (Tmz) in Newly Diagnosed Glioblastoma (Gbm)

416OA PHASE 1 STUDY EVALUATING ABT-414 WITH CONCURRENT RADIOTHERAPY (RT) AND TEMOZOLOMIDE (TMZ) IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM)

Managing toxicities and optimal dosing of targeted drugs in advanced kidney cancer

Targeted therapies for renal cell carcinoma: more gains from using them again

The Significance of Tracheobronchial Collapse in Obstructive Emphysema

Remediation of soils contaminated with polycyclic aromatic hydrocarbons (PAHs)

Simulation-based evolutionary optimization for energy-efficient layout plan design of high-rise residential buildings

Suchergebnisse filtern